"Enoxaparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
| Descriptor ID |
D017984
|
| MeSH Number(s) |
D09.698.373.400.300.200
|
| Concept/Terms |
PK-10,169- PK-10,169
- PK 10,169
- PK10,169
- PK-10169
- PK 10169
- PK10169
|
Below are MeSH descriptors whose meaning is more general than "Enoxaparin".
Below are MeSH descriptors whose meaning is more specific than "Enoxaparin".
This graph shows the total number of publications written about "Enoxaparin" by people in this website by year, and whether "Enoxaparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enoxaparin" by people in Profiles.
-
The use of enoxaparin as bridge to therapeutic INR after LVAD implantation. J Cardiothorac Surg. 2020 Nov 14; 15(1):329.
-
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty. J Am Acad Orthop Surg. 2018 Oct 01; 26(19):698-705.
-
Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio. ASAIO J. 2018 Mar/Apr; 64(2):140-146.
-
Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? Int J Surg. 2018 Mar; 51:128-132.
-
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
-
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
-
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
-
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. JAMA Surg. 2016 11 01; 151(11):1006-1013.
-
Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin. J Urol. 2017 02; 197(2):302-307.
-
The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. J Neurosurg Pediatr. 2015 Sep; 16(3):329-34.